{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:15:16Z","timestamp":1760548516058,"version":"3.37.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1124\/dmd.107.016865","type":"journal-article","created":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T00:59:11Z","timestamp":1192150751000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the \u03b1-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Collett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.H.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.L.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Warhurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.016865_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/10937400306466","article-title":"A role for P-glycoprotein in environmental toxicology","volume":"6","author":"Abu-Qare","year":"2003","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1124\/dmd.107.016865_bib2","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jps.20639","article-title":"Labetalol absorption kinetics: rat small intestine and colon studies","volume":"95","author":"Abushammala","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.107.016865_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1124\/dmd.107.015180","article-title":"Impact of physicochemical and structural properties on the pharmacokinetics of a series of \u03b11L-adrenoceptor antagonists","volume":"35","author":"Betts","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016865_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/1568026013394886","article-title":"Strategies for absorption screening in drug discovery and development","volume":"1","author":"Bohets","year":"2001","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.107.016865_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/mp050090k","article-title":"Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery","volume":"3","author":"Calcagno","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.107.016865_bib6","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1185\/030079906X132613","article-title":"Clinical spectrum of the osmotic-modified release oral delivery system (OROS), an advanced oral delivery form","volume":"10","author":"Conley","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/dmd.107.016865_bib7","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut"},{"key":"10.1124\/dmd.107.016865_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/17425247.3.1.23","article-title":"Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition","volume":"3","author":"Dey","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1124\/dmd.107.016865_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jps.20550","article-title":"Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics","volume":"95","author":"Eichenbaum","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.107.016865_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejps.2006.04.010","article-title":"Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells","volume":"29","author":"Englund","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.107.016865_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/bbrc.1995.1344","article-title":"The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug-resistance","volume":"208","author":"Gekeler","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.107.016865_bib12","first-page":"804","article-title":"Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system","volume":"16","author":"Gonz\u00e1lez","year":"1994","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.107.016865_bib13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/mp060042f","article-title":"The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests","volume":"3","author":"Kim","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.107.016865_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1464-410X.2004.05252.x","article-title":"Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction","volume":"9","author":"Kirby","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/dmd.107.016865_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.2042-7158.1997.tb06084.x","article-title":"Human jejunal effective permeability and its correlation with preclinical drug absorption models","volume":"7","author":"Lennernas","year":"1997","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.107.016865_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.107.016865_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1023\/A:1011971303880","article-title":"Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells","volume":"15","author":"Makhey","year":"1998","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.107.016865_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejps.2006.06.004","article-title":"Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract","volume":"29","author":"Masaoka","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.107.016865_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.36.2.259","article-title":"Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues","volume":"36","author":"McKinnon","year":"1995","journal-title":"Gut"},{"key":"10.1124\/dmd.107.016865_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/js950267+","article-title":"Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue","volume":"85","author":"Rubas","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.107.016865_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1023\/A:1016217505990","article-title":"Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine","volume":"9","author":"Saitoh","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.107.016865_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"10.1124\/dmd.107.016865_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejps.2006.03.003","article-title":"Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells","volume":"28","author":"Seithel","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.107.016865_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1021\/bp050208u","article-title":"Role of Caco-2 cell monolayers in prediction of intestinal drug absorption","volume":"22","author":"Shah","year":"2006","journal-title":"Biotechnol Prog"},{"key":"10.1124\/dmd.107.016865_bib25","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/sj.bjp.0704668","article-title":"Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a(-\/-) mice","volume":"135","author":"Stephens","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.107.016865_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1124\/jpet.102.041236","article-title":"Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-\/-) mouse intestine","volume":"303","author":"Stephens","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.016865_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00001622-200009000-00011","article-title":"Multidrug resistance transporters and modulation","volume":"12","author":"Tan","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1124\/dmd.107.016865_bib28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1359-6446(05)03551-8","article-title":"Assessment of the feasibility of oral controlled release in an exploratory development setting","volume":"10","author":"Thombre","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.107.016865_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejps.2006.04.005","article-title":"Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans","volume":"29","author":"Tubic","year":"2006","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 1","key":"10.1124\/dmd.107.016865_bib30","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0169-409X(01)00183-1","article-title":"Intestinal drug efflux: formulation and food effects","volume":"50","author":"Wagner","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.107.016865_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0169-409X(00)00135-6","article-title":"The role of \u03b3-scintigraphy in oral drug delivery","volume":"46","author":"Wilding","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.107.016865_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/js970218s","article-title":"Membrane transport of drugs in different regions of the intestinal tract of the rat","volume":"87","author":"Ungell","year":"1998","journal-title":"J Pharm Sci"},{"issue":"Suppl 6","key":"10.1124\/dmd.107.016865_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000052595","article-title":"The efficacy and safety of a new once-a-day formulation of an \u03b1-blocker","volume":"39","author":"Van Kerrebroeck","year":"2001","journal-title":"Eur Urol"},{"key":"10.1124\/dmd.107.016865_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/dmd.104.001354","article-title":"Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract","volume":"33","author":"Zimmermann","year":"2005","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562401537X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562401537X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.016865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:27:16Z","timestamp":1739896036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562401537X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S009095562401537X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.016865","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the \u03b1-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.016865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}